Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Learning to Navigate the Neoadjuvant and Adjuvant Paradigms in Pancreatic Cancer

June 11th 2018

Tanios Bekaii-Saab, MD, discusses neoadjuvant and adjuvant strategies in treating patients with early-stage pancreatic cancer.

Amid Success, Immunotherapy Faces Challenges in GI Malignancies

June 8th 2018

Gregory L. Beatty, MD, PhD, shares his insight on the challenges with sequencing immunotherapies in light of recent advancements in gastrointestinal malignancies.

Surgery Remains Vital in Hepatobiliary Neoplasms

June 8th 2018

Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.

Dr. Conroy Discusses Adjuvant mFOLFIRINOX in Pancreatic Cancer

June 7th 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the results of an adjuvant modified FOLFIRINOX regimen (mFOLFIRINOX) in patients with pancreatic cancer.

Ahn Recaps Advances and Challenges in Gastric/GEJ Cancers

June 7th 2018

Daniel Ahn, DO, discusses advances and challenges with targeted and immune-based therapies in the treatment of patients with gastric and gastroesophageal cancer.

Ramucirumab Extends Survival in Advanced HCC

June 6th 2018

Second-line ramucirumab (Cyramza) reduced the risk of death by 29% versus placebo in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein.

Chemoprevention Reduces Risk for Esophageal Cancer

June 5th 2018

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

Dr. Ramanathan Discusses the Treatment of Pancreatic Cancer

June 5th 2018

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.

Pancreatic Cancer Survival Jumps With Postsurgical Chemo Combo

June 4th 2018

A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.

Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer

June 4th 2018

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

June 4th 2018

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

FDA Accepts Cabozantinib Application for Advanced HCC

May 30th 2018

The FDA has accepted a supplemental new drug application for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma.

Dr. Atreya Discusses Maintenance Therapy for CRC

May 29th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

FDA Delays Decision on Lenvatinib for HCC

May 25th 2018

The FDA has extended the review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma. The new action date for the supplemental new drug application is August 24, 2018.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer

May 23rd 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care

May 23rd 2018

Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

Dr. Ramanathan on Emerging Therapeutic Targets in Patients With Pancreatic Cancer

May 22nd 2018

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses emerging therapeutic targets in patients with pancreatic cancer.

Dr. O'Neil on Neuroendocrine Tumors

May 22nd 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).